Related Experiment Video
Updated: Dec 24, 2025
Isolation and Expansion of Mesenchymal Stem/Stromal Cells Derived from Human Placenta Tissue
Published on: June 6, 2016
Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia
S Suvakov1,2, C Richards3, V Nikolic4
1Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Insights
Mesenchymal stem/stromal cells (MSCs) show promise for treating preeclampsia, a dangerous pregnancy condition. MSCs, acting via paracrine signaling, offer immunomodulatory and regenerative effects, supporting further clinical trials for this disease.
Area of Science:
- Reproductive Medicine
- Immunology
- Regenerative Medicine
Background:
- Preeclampsia is a severe pregnancy complication with unknown causes, impacting maternal and fetal health.
- Key pathogenic factors include maternal immune response, inflammation, oxidative stress, and endothelial dysfunction.
- Current treatments for preeclampsia are limited, necessitating novel therapeutic approaches.
Purpose of the Study:
- To provide a comprehensive review of mesenchymal stem/stromal cells (MSCs) as a potential therapeutic strategy for preeclampsia.
- To elucidate the mechanisms underlying MSC-based therapies in the context of preeclampsia.
- To assess the current evidence supporting MSCs for preeclampsia treatment.
Main Methods:
- Review of existing literature on MSCs and their therapeutic potential in preeclampsia.
- Analysis of MSC properties, including low immunogenicity and in vitro expansion capabilities.
- Examination of preclinical studies in animal models of preeclampsia.
Main Results:
- MSCs exert therapeutic effects primarily through paracrine signaling via their secretomes.
- These secretomes mediate potent immunomodulatory, pro-angiogenic, and regenerative actions.
- Preclinical studies in preeclampsia animal models have yielded promising outcomes.
Conclusions:
- MSCs represent a promising cell-based therapy for preeclampsia.
- Further research into MSC mechanisms and therapeutic efficacy is warranted.
- Clinical trials are a logical next step to evaluate MSC-based treatments for preeclampsia.
Purpose Of Review:
Preeclampsia is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development. Here, we give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia.
Recent Findings:
MSCs have gained growing attention due to low immunogenicity, easy cultivation and expansion in vitro. Accumulating evidence now suggests that MSCs act primarily through their secretomes facilitating paracrine signalling that leads to potent immunomodulatory, pro-angiogenic and regenerative therapeutic effects. MSCs have been studied in different animal models of preeclampsia demonstrating promising result, which support further investigations into the therapeutic effects and mechanisms of MSC-based therapies in preeclampsia, steering these therapies into clinical trials.
